Recent advancements in immunotherapy demonstrate that viral capsids and virus-like particles can be engineered to deliver receptor-based constructs like CARs to target cancer cells.
Viral capsids and virus-like particles can be engineered to deliver receptor-based constructs to target cancer cells.